Dr. Robert G. Szewc, M.D. FASN
Board Certified In Nephrology – Interventional Nephrologist Internal Medicine
Dr. Robert’s Szewc (Chefs) mission and life work are dedicated to provide the best kidney care possible and to preserve, maintain, or reverse kidney failure.
Focusing on preventative care and patient education empowers patients and their families to improve their health and quality of life.
RESEARCH EXPERIENCE
LIFEVEST
LIFEVEST – Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED_HED) Study.
Sponsor: ZOLL, Sub-Principal Investigator: Robert G. Szewc, MD, 03/15.
ROXADUSTAT
ROXADUSTAT – A Phase 3, Multicenter, Randomized, Double–Blind, Placebo–Controlled Study Evaluating the Safety and Efficacy of XX-XXX for the Treatment of Anemia in Chronic Disease Patients not on Dialysis.
Sponsor: AstraZeneca, Principal Investigator: Robert G. Szewc, MD. 11/14
PHOSPHATE
PHOSPHATE – A Multicenter, Double – Blind Placebo – Controlled Randomized Study to Evaluate the Efficacy and Safety of XX-XXX in Subjects with Hyperphosphatemia and Dialysis – Dependent Chronic Disease.
Sponsor: Phosphate Therapeutics Ltd. (PTL) Principal Investigator: Robert G. Szewc, MD 04/14
AGMEN
AGMEN – A Randomized, Double – Blind, Placebo Controlled Study to Assess the Efficiency and Safety of Cinacalcet HCL in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism not Receiving Dialysis (Protocol 20000178.) Sub – Principal Investigator: Robert G. Szewc, MD 2005 – 2006
ABBOTT
ABBOTT – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Safety and Efficacy of Zemplar Capsule in reducing Serum Intact Parathyroid Levels in Chronic Kidney Disease Stage V Subjects in Hemodialysis or Peritoneal Dialysis (Protocol M03-635) Sub-Principal Investigator: Robert G. Szewc, MD 2004-2005.
AMGEN INC
AMGEN INC – A Placebo-Controlled, Double-Blinded, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis) (Protocol 20000188.) Sub-Principal Investigator: Robert G Szewc, MD 2002-2003.
NATIONAL INSTITUTE OF HEALTH
NIH – Family Investigation of Nephrology in Diabetes (FIND) 2002-2003
PATIROMER
PATIROMER – The Effect of Food: An Open – Labeled, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension with or without food for the treatment of Hyperkalemia (TOURMALINE.) Sub- Principal Investigator: Robert G. Szewc, MD, 03/15
NABI PHARMACEUTICALS, INC – A Phase III, Multicenter, Randomized, Placebo- Controlled, Double – Blinded Study to Evaluate Efficacy of Staph V AX, a Blvalent Staphylococcus Eureus Glycocanjugate Vaccine In Adults on Hemodialysis (Protocol 1371) Sub-principal Investigator: Robert G Szewc, MD 2004-2005
AMGEN INC – A Placebo-Controlled, Double-Blinded, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis) (Protocol 20000188.) Sub-Principal Investigator: Robert G Szewc, MD 2002-2003.
ABBOTT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Study to Evaluate the Safety and Efficacy of Zemplar Capsule (Dosed Three Times Weekly) in reducing Elevated Serum Intact Parathyroid Hormone Levels in Subject with Chronic Kidney Disease (Protocol 2001020). Principal Investigator: Robert G. Szewc MD 2002-2003
NIH – Family Investigation of Nephrology in Diabetes (FIND) 2002-2003
ABBOT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety of Xemplar Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Hemodialysis (Protocol 2001-013)
Principal Investigator: Robert G Szewc 2002-2003
KERYX
KERYX – A Phase 3 Study of XX-XXX for the treatment of Iron Deficiency Anemia in Adult Subject with Non-Dialysis Dependent Chronic Kidney Disease.
Sponsor: Keryx Biopharmaceuticals, Principal Investigator: Robert G. Szewc 09/14
SHIRE
SHIRE – A Phase IV, Open- Label, Multi- Center Trial Evaluation the Efficacy of Fosrenal (Lanthum Carbonate) Compared to Existing Therapy in Adults with End Stage Renal Disease Treated for Hyperphosphatemia, (Protocol SPD 405 – 401) Principal Investigator: Robert G. Szewc, MD 2005 – 2006
ABBOTT LABORATORIES, INC
ABBOTT LABORATORIES, INC – A Phase IV, Prospective, Randomized, Active – Controlled, Double- Blind, Double – Dummy, Multi – Center study to Evaluate the Survival Benefits of Zemplar Relative to Calcilex in Subjects with Stave V Chronic Kidney Disease on Hemodialysis. (Protocol M02 – 516) Sub – Principal
Investigator: Robert G. Szewc, MD. 2003 – 2004
NABI PHARMACEUTICALS, INC
NABI PHARMACEUTICALS, INC – A Phase III, Multicenter, Randomized, Placebo- Controlled, Double – Blinded Study to Evaluate Efficacy of Staph V AX, a Blvalent Staphylococcus Eureus Glycocanjugate Vaccine In Adults on Hemodialysis (Protocol 1371) Sub-principal Investigator: Robert G Szewc, MD 2004-2005
ABBOTT LABORATORIES INC
ABBOTT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Zemplar Capsule (Dosed Three Times Weekly) in reducing Elevated Serum Intact Parathyroid Hormone Levels in Subject with Chronic Kidney Disease (Protocol 2001020). Principal Investigator: Robert G. Szewc MD 2002-2003
ABBOT LABORATORIES INC
ABBOT LABORATORIES INC. – A Phase III, Prospective, Randomized, Placebo-Controlled, Double- Blind, Multicenter, Study to Evaluate the Safety of Xemplar Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Hemodialysis (Protocol 2001-013)
Principal Investigator: Robert G Szewc 2002-2003
PUBLICATIONS
Treatment of Symptomatic Coronary Artery Disease in Patients with End-Stage Renal Disease on Hemodialysis with Paclitaxel-eluting TAXUS Stent
Treatment of Symptomatic Coronary Artery Disease in Patients with End-Stage Renal Disease on Hemodialysis with Paclitaxel-eluting TAXUS Stent. Szymon L Wiernek, R. Stefan Jiesz, Barbara K. Wiernek, Portr P. Buzman, Adam Janas, Jack L. Martin, Blazej Trela, Robert G. Szewc, Pawel E Buszman. Hemodialysis International 2015;19:402-411.
Prediction of GFR in Liver Transplant Candidates
Prediction of GFR in Liver Transplant Candidates. Skluzacek PA, R.G. Szwec, Nolan CR 3rd Riley DJ, Lee S, Pergola PE. Department of Medicine, Wilford Ha; Medical Center, Lackland Air Force Base, San Antonio, Texas; Am J Kidney Dis. 2003 Dec. 42(6); 1169-76
Plaque Excision Below the Knee for Limb Salvage in Patients with End Stage Renal Disease and Diabetes
Plaque Excision Below the Knee for Limb Salvage in Patients with End Stage Renal Disease and Diabetes. R.S. Kiesz, P. Buszman, M.A. Walker, R.G.Szewc, M.W. McQueen, San Antonio Endovascular and Heart Institue; Silesian Medical School, Katowice, Poland; Catheterization and Cardiovascular Interventions. 2006 May; 67 (5): 755. Also to be published in European Heart Journal 2006.
Renal Stenting with Distal Embolization Protection Prospective Registry; Preliminary Experience
Renal Stenting with Distal Embolization Protection Prospective Registry; Preliminary Experience, R.S. Kiesx, R. Szewc, T. Ybarra, M. Walker. San Antonio Endovascular and Heart Institute, San Antonio, Texas, Catheterization and Cardiovascular Interventions. 2005 May; 65(1): 152.